18 November 2021
Dr. Vladimir Cmiljanovic, CEO and founder of Swiss Rockets AG and RocketVax AG, has been named as the recipient of the 2021 Nikola Tesla Award for his accomplishments in the field of science.
Nikola Tesla Award is a prestigious, national award given by the Government of the Republic of Serbia and the Ministry of Foreign Affairs. The laureates of this award are prominent individuals of Serbian origin who have contributed to the promotion of Serbia and the strengthening of ties between the motherland and Serbs in the region and the diaspora.
Dr. Vladimir Cmiljanovic has been named as the recipient of the Nikola Tesla Award for advocating the achievements of Serbian scientists in the world through his scientific attainments in the field of oncology, as well as for leading the team of experts in the development of the second generation of SARS-CoV-2 vaccine.
Since the award is of national importance, official state institutions and media representatives paid special attention to this event.
To read the full report given by The Government of the Republic of Serbia, click on the file below:
To see the interviews that Dr. Vladimir Cmiljanovic gave on this occasion, watch the videos below:
Source: PRVA TV
Source: K1 TV/Youtube
30 September 2021
“The research team of the company ‘Swiss Rockets‘ is working on a vaccine based on a weakened coronavirus,” explains the guest of the ‘Morning program’, Dr. Vladimir Cmiljanovic. “It will be a second-generation vaccine that, unlike the first-generation vaccines, such as the mRNA or the Oxford and Russian vaccines, which have only spike protein as […]
19 August 2021
“Two new vaccines against COVID-19, using the recombinant protein technique, could be added to the vaccine range by the end of the year. One of them will be a Swiss vaccine: RocketVax.” To read the full interview with Dr. Vladimir Cmiljanovic, CEO of RocketVax, click on the document below. L’Avenir_2021_08_06 Source: L’Avenir Share
06 August 2021
“Founded in 2020, Basel-based company RocketVax has just secured funding to launch the pre-clinical phase of its Covid-19 vaccine development”. To read the full article published by Le Temps, click on the file below. LeTemps_2021_08_05 Source: Le Temps Share
23 July 2021
“RocketVax, a Basel-based company, has cleared another hurdle in the production of its new vaccine. It should protect longer and better against the coronavirus, as well as be able to be delivered all over the world.” BZ Basel is reporting about RocketVax’s SARS-CoV-2 vaccine. To read the full article, open the document below: BZ_Basel_20210716 Source: […]
29 June 2021
Bajour is reporting about the creativity and potential of startup pharma companies. Among others, they presented the RocketVax project, the second-generation SARS-CoV-2 vaccine, led by Prof. Dr. Thomas Klimkait. To read the full article, click on the link below: bajour.pdf Source: bajour.ch Share